Topic summary

Tirzepatide storage and stability: what is published versus what is assumed

Compounds › Tirzepatide SURPASS programme randomised trial SURMOUNT programme effect size tirzepatide

This is a generated summary. It shows the 5 most-liked posts from a topic of 22, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.

in.guerreroTL211 Jul 2026 · edited#4

Grateful for the specificity. Vague answers to this question are what sent me looking.

28 likes 17d

s.demirTL212 Jul 2026#8

Answering the question post #5 raises rather than the one it answers.

Dual agonism versus dose: how much of tirzepatide's effect is the GIP component and how much is simply achieving higher receptor engagement? The honest answer is that the question is not settled. Some of the effect is surely the GIP component, but the trial design does not decompose it.

This is the sort of thing the wiki should carry and currently does not.

21 likes 16d

c.wijnbergTL2Member13 Jul 2026#11

That matches what I have seen, for whatever a single anecdote is worth.

29 likes 15d

h.falkTL216 Jul 2026 · edited#20

CFairweather, post #7: Nausea profile: some people report tirzepatide as less nausea-prone than semaglutide, others report it as more. The trial reported gastrointestinal effects broadly comparable in character. Individual variation is the largest factor. This is the sort of thing that ought to be settled and apparently is not. Go to post

This is the sort of exchange that makes the archive worth searching.

28 likes in reply to #7 12d

l.aaltonenTL3Regular16 Jul 2026#21

The five maintenance doses in the tirzepatide programme give a genuine dose-response curve, which is unusual. Most trials in this space compare one or two doses against placebo and cannot say anything about the shape of the relationship.

Old habit: I write down the expected answer before I calculate it.

32 likes 12d

Read the full topic (22 posts)

This topic was referenced in

The 2.5 mg starting dose is not a therapeutic dose — why that mattersCompounds › Tirzepatide · 136 replies

Suggested topics

Topic	Participants	Replies	Views	Activity
SURMOUNT-4 and what withdrawal data does and does not tell an individual — one year on Compounds › Tirzepatide SURMOUNT programme randomised trial tirzepatide SURPASS programme Solved Closed Posting this under the heading it deserves: SURMOUNT-4 and what withdrawal data does and does not tell an individual — one year on Everything below is what sits behind that. I would like to disagree carefully…	+122	136	48k	9mo
About the Tirzepatide category Compounds › Tirzepatide tirzepatide SURMOUNT programme SURPASS programme Pinned Wiki Dual GIP/GLP-1 receptor agonist. SURPASS and SURMOUNT programme data, titration, and comparative discussion. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is…	+2	6	132	13mo
SURPASS-2 and the comparator dose question that will not go away — what changed since Compounds › Tirzepatide SURMOUNT programme tirzepatide effect size Posting this under the heading it deserves: SURPASS-2 and the comparator dose question that will not go away — what changed since Everything below is what sits behind that. What changes if the standard…	+2	6	5.5k	7h
Tirzepatide storage and stability: what is published versus what is assumed — does this still hold? Compounds › Tirzepatide tirzepatide SURPASS programme effect size The question in the title: Tirzepatide storage and stability: what is published versus what is assumed — does this still hold? I will give what I have already checked below so nobody repeats it. Asking about…	+15	19	930	18mo
What the GIP component of tirzepatide is thought to contribute, and how confident we can be Compounds › Tirzepatide tirzepatide SURPASS programme SURMOUNT programme effect size Solved What the GIP component of tirzepatide is thought to contribute, and how confident we can be I have a specific reason for asking rather than idle curiosity, and the context is below. I would like to know what…	+16	20	23k	19h

Related topics — sharing the tags SURPASS programme, randomised trial, SURMOUNT programme

Topic	Participants	Replies	Views	Activity
The C-cell question: rodent findings and their human context Compounds › Semaglutide STEP programme type 2 diabetes effect size Closed Posting this under the heading it deserves: The C-cell question: rodent findings and their human context Everything below is what sits behind that. The question about c-cell question that I actually want…	+41	45	24k	12mo
What the published dose-response for semaglutide actually looks like above 2.4 mg Compounds › Semaglutide STEP programme type 2 diabetes effect size SELECT trial Solved What the published dose-response for semaglutide actually looks like above 2.4 mg — that is the question, and I have not found it answered plainly anywhere I have looked. I would like to know what people here…		2	10k	3mo
Micro-titration: a disputed topic, argued properly Practice › Dosing & titration titration dose reduction worked example tirzepatide Solved Wiki Micro-titration: a disputed topic, argued properly Writing it up because I had to work it out twice and would rather nobody else did. Two things I would like separated before anyone answers on…	+99	110	61k	2d
A well-designed study with a badly written abstract Evidence › Study critique disputed effect size risk of bias observational data Posting this under the heading it deserves: A well-designed study with a badly written abstract Everything below is what sits behind that. Reading back through what has been written here about well-designed…	+117	128	7.2k	14mo
Coming back to: Why most self-reports here are not experiments, and that is fine Research Methods › N-of-1 designs worked example data table effect size Solved Closed The question in the title: Why most self-reports here are not experiments, and that is fine I will give what I have already checked below so nobody repeats it. A question about what a single-person experiment…	+56	62	11k	4mo